NCT07112287

Germline Testing for Predisposition to Myeloid Malignancies

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Christopher Reilly · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Detailed description

This prospective, single arm study aims to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies. Investigators hope to learn how to best incorporate routine genetic testing in clinical care for participants with blood cancers, regardless of personal or family history of blood cancer. The research study procedures include screening for eligibility, in-clinic visits, questionnaires, and punch skin biopsies. It is expected that about 200 people will take part in this research study. The laboratory sponsor of this protocol is Broad Clinical Laboratory.

Conditions

• Myeloid Malignancy
• Genetic Predisposition to Disease
• Myeloid Hematological Malignancies

Interventions

Type	Name	Description
DEVICE	MyeloGen Gene Panel	The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

Timeline

• Start date: 2026-02-01
• Primary completion: 2030-04-01
• Completion: 2033-04-01
• First posted: 2025-08-08
• Last updated: 2025-08-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study